Inhibitor
| Cat.No. | Name | Information |
|---|---|---|
| M58440 | Soquelitinib | Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease. Soquelitinib increases tumor infiltration of normal CD8+ cells that possess enhanced T effector function. |
| M43518 | ITK degrader 2 | ITK degrader 2 is a modulator of targeted ubiquitination and a targeted protein degrading molecule. |
| M43517 | ITK degrader 1 | ITK degrader 1 is a highly selective degrader of interleukin-2-inducible T-cell kinase (ITK; DC50=3.6 nM in vivo in mice). |
| M28620 | PRN694 | PRN694 is an irreversible, highly selective and potent covalent interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) dual inhibitor with IC50s of 0.3 nM and 1.4 nM, respectively. PRN694 exhibits extended target residence time on ITK and RLK, enabling durable attenuation of effector cells in vitro and in vivo. |
| M28596 | GNE-9822 | GNE-9822 is a potent, orally active and selective ITK inhibitor with a Ki value of 0.7 nM. GNE-9822 has good ADME properties. GNE-9822 can be used in research of asthma. |
| M28149 | ITK inhibitor 2 | ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor, with an IC50 of 2 nM. |
| M27849 | ITK antagonist | ITK antagonist (compound 10 n) is a potent, orally active and selective ITK (Interleukin-2 inducible T-cell kinase) antagonist (IC50=1 and 20 nM in different assays). ITK antagonist inhibits insulin receptor kinase (IRK) with an IC50 of 160 nM. |
| M11467 | GSK-2250665A | GSK-2250665A is a Itk inhibitor with pKi value of 9.2. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
